Photo by sxy_selia from unsplash
Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS… Click to show full abstract
Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.
Keywords:
patients parkinson;
sleepiness patients;
daytime sleepiness;
parkinson disease;
reduces daytime;
selegiline reduces
Journal Title: Brain and Behavior
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Brain and Behavior
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!